Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019
- Company Expects to Initiate Phase 3 Clinical Trials Next Year PASADENA, Calif. --(BUSINESS WIRE)--Nov. 18, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented updated Phase 1 clinical data on its two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Planned Management Transition
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 15, 2019-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Bruce Given , M.D., Arrowhead’s chief operating officer and head of R&D, plans to retire on May 1, 2020 , after a more than 30 year career in biotechnology and pharmaceutical
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 11, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2019 , at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2019 .
View HTML
Toggle Summary Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 8, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced Phase 2 clinical data on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA), and the first clinical data on a triple combination of JNJ-3989, JNJ-6379,
View HTML
Toggle Summary Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 31, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at the 2019 North American Cystic Fibrosis Conference (NACFC) on ARO-ENaC, an inhaled RNAi therapeutic being developed as a potential treatment for cystic fibrosis
View HTML
Toggle Summary Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 18, 2019-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule Platform (TRiM™) platform.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics
  PASADENA, Calif. --(BUSINESS WIRE)--Oct. 2, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule (TRIM TM ) platform from
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences
  PASADENA, Calif. --(BUSINESS WIRE)--Sep. 30, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:   2019 Cantor Global Healthcare Conference   – New York , October 2-4, 2019     October 4 , 10:05 a.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 20, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 13, 2019 , the Compensation Committee of the Board of Directors approved "inducement" grants to 17 new
View HTML
Toggle Summary Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 16, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented initial top-line clinical data at The Global Summit on Cardiology and Heart Diseases, being held in Dubai , UAE . The data demonstrate that, in two Phase I single-dose clinical studies
View HTML